BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 21656749)

  • 41. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
    Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
    Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
    Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H
    Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
    Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y
    Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
    Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
    Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.
    Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y
    J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
    Martelli MP; Sozzi G; Hernandez L; Pettirossi V; Navarro A; Conte D; Gasparini P; Perrone F; Modena P; Pastorino U; Carbone A; Fabbri A; Sidoni A; Nakamura S; Gambacorta M; Fernández PL; Ramirez J; Chan JK; Grigioni WF; Campo E; Pileri SA; Falini B
    Am J Pathol; 2009 Feb; 174(2):661-70. PubMed ID: 19147828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
    Solomon B; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2009 Dec; 4(12):1450-4. PubMed ID: 20009909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel ALK fusion partners in lung cancer.
    Iyevleva AG; Raskin GA; Tiurin VI; Sokolenko AP; Mitiushkina NV; Aleksakhina SN; Garifullina AR; Strelkova TN; Merkulov VO; Ivantsov AO; Kuligina ESh; Pozharisski KM; Togo AV; Imyanitov EN
    Cancer Lett; 2015 Jun; 362(1):116-21. PubMed ID: 25813404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
    Alì G; Proietti A; Niccoli C; Pelliccioni S; Borrelli N; Giannini R; Lupi C; Valetto A; Bertini V; Lucchi M; Mussi A; Fontanini G
    Lung Cancer; 2013 Aug; 81(2):297-301. PubMed ID: 23664446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.